Prophylaxis of catheter-related thrombosis in cancer patients

The Lancet

Volumn 373, Issue 9663, 2009, Pages 523-524

  Prandoni, Paolo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10A INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ARTICLE; CANCER PATIENT; CATHETER THROMBOSIS; CENTRAL VENOUS CATHETER; CLINICAL DECISION MAKING; COMORBIDITY; DEEP VEIN THROMBOSIS; FAMILY HISTORY; HUMAN; INDWELLING CATHETER; INTERNATIONAL NORMALIZED RATIO; LOW DRUG DOSE; PATIENT ASSESSMENT; PATIENT COMPLIANCE; PHYSICIAN; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; THERAPY EFFECT; THROMBOPHILIA; THROMBOSIS PREVENTION; TREATMENT INDICATION; TREATMENT RESPONSE;

EID: 59749090712     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)60178-1     Document Type: Note

References (12)

1. Verso M., and Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol 21 (2003) 3665-3675
2. Bern M.M., Lokich J.J., Wallach S.R., et al. Very low dose of warfarin can prevent thrombosis in central venous catheters: a prospective trial. Ann Intern Med 112 (1990) 423-428
3. Monreal M., Alastrue A., Rull M., et al. Upper extremity deep venous thrombosis in cancer patients with venous access devices-prophylaxis with a low molecular weight heparin (fragmin). Thromb Haemost 75 (1996) 251-253
4. Couban S., Goodyear M., Burnell M., et al. Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol 23 (2005) 4063-4069
5. Karthaus M., Kretzschmar A., Kroning H., et al. Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. Ann Oncol 17 (2005) 289-296
6. Lee A.Y., Levine M.N., Butler G., et al. Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. J Clin Oncol 24 (2006) 1404-1408
7. Verso M., Agnelli G., Bertoglio S., et al. Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. J Clin Oncol 23 (2005) 4057-4062
8. Carrier M., Tay J., Fergusson D., and Wells P.S. Thromboprophylaxis for catheter-related thrombosis in patients with cancer: a systematic review of the randomized, controlled trials. J Thromb Haemost 5 (2007) 2552-2554
9. Chaukiyal P., Nautiyal A., Radhakrishnan S., Singh S., and Navaneethan S.D. Thromboprophylaxis in cancer patients with central venous catheters; a systematic review and meta-analysis. Thromb Haemost 99 (2008) 38-43
10. Geerts W.H., Bergqvist D., Pineo G.F., et al. Prevention of venous thromboembolism: American College of Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133 suppl 6 (2008) 381S-453S
11. Young A.M., Billingham L.J., Begum G., et al., on behalf of the WARP Collaborative Group UK. Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial. Lancet 373 (2009) 567-574
12. Verso M., Agnelli G., Kamphuisen P.W., et al. Risk factors for upper limb deep vein thrombosis associated with the use of central vein catheter in cancer patients. Intern Emerg Med 3 (2008) 117-122